Join us on the latest episode! Our Guest: Javier Swarcberg, CEO of Spruce Biosciences
What you'll get out of this episode:
- Dive deep into the world of Congenital Adrenal Hyperplasia (CAH) treatments and drug development.
- Understand the challenges and rewards of addressing rare diseases, especially in pediatrics.
- Javier Szwarcberg discusses Spruce's innovative Tildesophon and its potential impact on the CAH therapeutic landscape.
- Discover the upcoming clinical updates from Spruce Biosciences and the promising future outlook for CH treatments.
To learn more about Spruce Biosciences: https://sprucebio.com/
Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
